Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

The primary endpoint was met: partial response in 8/27 (ORR 30%, 95% CI 12-47%). Disease control (PR plus SD lasting more than 4 months) was 59%. Median PFS was 16 weeks. This is metastatic anti-EGFR rechallenge guided by ctDNA resistance mutations, not adjuvant MRD.

ASCO Annual Meeting 2021